Cited 2142 times in
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.